| 2026-08-13 | Press release | Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights |
| 2026-06-02 | Press release | Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-28 | Press release | Equillium to Participate in the 2026 Jefferies Global Healthcare Conference |
| 2026-05-27 | Presentation | Insights into the Aryl Hydrocarbon Receptor and miR-124 Axis(opens in new window) |
| 2026-05-20 | Press release | Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis |
| 2026-05-13 | Press release | Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights |
| 2026-05-01 | Press release | Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-01 | Presentation | Download(opens in new window) |
| 2026-04-20 | Press release | Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event |
| 2026-04-08 | Press release | Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunolog |
| 2026-04-02 | Press release | Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-18 | Press release | Equillium to Participate in the 38th Annual Roth Conference |
| 2026-03-13 | Press release | Equillium Announces $35 Million Financing with RA Capital Management |
| 2026-02-25 | Press release | Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference |
| 2026-02-02 | Press release | Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-11-13 | Press release | Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update |
| 2025-11-05 | Presentation | Equillium Virtual KOL Event to Discuss EQ504: A Novel Aryl Hydrocarbon Receptor (AhR) Modulator for Ulcerative Colitis |
| 2025-03-27 | Presentation | Phase 3 EQUATOR Data Presentation |
| 2024-06-03 | Presentation | Presentation |
| 2023-10-16 | Presentation | Equillium Analyst & Investor Day |
| 2023-02-16 | Presentation | Final Safety and Efficacy Results from EQUATE, an Open-Label Study Evaluating Itolizumab, a Novel Targeted anti-CD6 Ther |
| 2022-11-03 | Presentation | EQ101: A Multi-specific Cytokine Inhibitor to Treat Alopecia Areata<span>Steve Connelly</span><span>Dermatology Drug Dev |
| 2022-04-06 | Presentation | Targeting the CD6-alcam T Cell Costimulatory Pathway After Allogeneic Cell Transplantation for Acute Graft Versus Host D |
| 2022-03-23 | Presentation | Updated Interim Results From the EQUATE Study: Preliminary Safety and Efficacy of Itolizumab, A Novel Targeted Anti-CD6 |
| 2022-03-23 | Presentation | Itolizumab, a Novel Targeted Anti-CD6 Therapy, Induces Cleavage of Cell Surface CD6 and Rapid Onset of Efficacy in Subje |
| 2021-11-05 | Presentation | Itolizumab, a Novel Anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b |
| 2021-02-21 | Presentation | Early reconstitution of cd6+ t cells after hematopoietic cell transplantation identifies a suitable target for acute gra |